Amgen, colorectal cancer

US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation. Amgen's Lumakras in combination with Vectibix was approved to treat adult patients whose cancer has spread to other parts of the body despite receiving chemotherapy,
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median progression-free survival (PFS) of 5.6 months compared to 2 months on the investigator’s choice of care (n=54).
Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer
Lumakras (sotorasib) and Vectibix (panitumumab) have been authorised for use in adults with KRAS G12C-mutated metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
Amgen announces FDA approval of Lumakras in combination with Vectibix
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS
FDA approves new colorectal cancer treatment
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) to treat adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC) whose tumors harbor an abnormal gene known as KRAS G12C.
Piper Sandler maintains Amgen stock Overweight with $310 target
Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...
FiercePharma8h
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
BioPharma Dive3h
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
GlobalData on MSN3d
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entrance
Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
Amgen’s $1 billion expansion in Holly Springs includes 12 apprentices from Wake Tech
Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
Amgen Inc. stock underperforms Tuesday when compared to competitors
Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.